High response rates with bevacizumab, docetaxel, and carboplatin in patients with HER2-negative advanced breast cancer: An experience of 22 case reports.

Abstract

e11538 Background: Monoclonal antibodies, such as bevacizumab, stop tumor growth and block the ability of tumor cells to grow and spread. Others drugs find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as docetaxel and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with docetaxel and carboplatin may kill more tumor cells. The aim of this study was to determine the clinical response rate in women with metastatic breast cancer and Her2 negative treated with bevacizumab, docetaxel, and carboplatin. Methods: Twenty two patients Her2 negative with diagnostic of metastatic breast cancer were included and received bevacizumab (15mg/kg), docetaxel (75mg/m2), and carboplatin (AUC 5) on day 1 and were repeated every 3 weeks for 6-8 courses in the absence of disease progression or unacceptable toxicity. Results: Overall clinical response rate was 80% (18/22) and it was assessed by RECIST criteria using CT and PET-CT. Surprisingly, the complete clinical response rate was about 40% (9/22) in all patients. Progression disease-free survival was between 7-14 months. At this moment 22% (5/22) of patients have been recurred. Safety and tolerability were acceptable; in only 9% (2/22) patients were observed an acute anaphylactic response (dysnea, hyperthermia, anxiety and puritus) without serious adverse events. Conclusions: This study strongly suggests that the inclusion of bevacizumab in combination with docetaxel and carboplatin do not increase the toxicity profile previously reported for these chemotherapy drugs and increase the clinical response rate. At this moment there is not previous report about the use of these agents combination in Her2 negative advanced breast cancer patients and it could be a very hopeful new treatment for this kind of patients. A new prospective study with a large patient number we consider for a near future.